Latest

FDA Opens Door to Importing Scarce and Costly Drugs

Rising pressure to access less expensive prescription medicines available overseas is prompting the Trump administration to explore flexible import policies, reports Jill Wechsler.

The Diabetes Market in China

With China predicted to account for 48% of the global diabetes population by 2045, Jin Zhang looks at how the country's domestic pharma companies are faring in this treatment area.

Does the Pfizer Restructuring Make Sense?

The Pfizer restructuring will be a case study in whether corporate restructuring & innovation can co-exist or whether M&A is the more viable answer, writes Edward Pratesi.

The Key to Better Navigating VUCA Industry Conditions

Alison Horstmeyer discusses how pharma executives can apply four attributes of curiosity to negotiate VUCA (volatile, uncertain, complex, and ambiguous) conditions and improve organizational outcomes.

Pharm Exec Video

Behind the Scenes with Kallyope’s Nancy Thornberry

A sneak peek at Pharm Exec's August cover shoot with the New York City-based biotech CEO.

Why One Korean Biotech Picked New Jersey for U.S. Headquarters

New Jersey is still a top pick for companies when it comes to pharma.

Pharm Exec Talks Partnerships with Sanofi

Hear what Sanofi looks for when they decide to form a partnership with another company.

New & Noteworthy

Enabling Cultural Change in Organizations

New ideas and technological advances are two key methods leading to culture change in an organization. Graham Francis reports.

Patient & Customer-Centric Commercialization

Outlining a real-world case study in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”

Opioid Litigation: Evading the Widening Crosshairs

The role of insurance and risk management in protecting middle-market distributors from the growing opioid multi-district litigation (MDL).

Compliance: The Critical Cog in Pharma Machine

Pharm Exec convenes an expert panel to discuss new ways to navigate the many complexities of assessing business and risk in the life sciences.

Sales & Marketing

Patient Communications: Why Pharma Leaders Should Think Like Social Marketers

By exploring how social marketers think, pharma can unlock tried-and-tested ways to bring measurable value to their patients, write Patrick Ladbury and Oliver Childs.

Connecting the 5 Spheres of People-Based Marketing

From persistent identity to cloud marketing driven by AI, managing holistic experience is now the hallmark of brand leadership. Croom Lawrence and Kent Groves explains how people-based marketing plays a key role.

Leveraging Lab Data in Advent of Personalized Marketing

Laboratory testing has become a critical access point for sales teams in the age of personalized medicine, writes Melissa Leonhauser.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

European Drug Innovators Face Tough Fight to Maintain Research Incentives

Research-based companies in Europe look as though they have lost one battle on preserving incentives for innovation – but the bigger war is only now getting underway, writes Reflector.

Blockchain 101 for Pharma Executives

With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you?

China’s Biopharma Rise: Opportunities and Threats

Peter Young explores the prospects—and related challenges—for Chinese life science as it aggressively pursues new growth areas.

Pharm Exec's Top 50 Companies 2018

Pharm Exec’s 18th annual listing of the top biopharma players shows that most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth.

Interviews

Gaining Ground with Stem Cells: Gil Van Bokkelen, Athersys

PharmExec talks to Dr. Gil Van Bokkelen, co-founder of Athersys, a company looking to forge new advances in the stem cell arena.

EMA Relocation Countdown: Some Industry Viewpoints

Raman Sehgal talks to three industry leaders for their insights on the challenges faced across the life science sector and how the EMA needs to respond.

Regulatory Information Management: Current and Future States

Steve Gens talks to Pharm Exec about the evolution of Regulatory Information Management (RIM) and offers some predictions for 2022.

Regulatory

FDA Opens Door to Importing Scarce and Costly Drugs

Rising pressure to access less expensive prescription medicines available overseas is prompting the Trump administration to explore flexible import policies, reports Jill Wechsler.

EMA Relocation Countdown: Some Industry Viewpoints

Raman Sehgal talks to three industry leaders for their insights on the challenges faced across the life science sector and how the EMA needs to respond.

Regulatory Innovation Generates Breakthroughs

Streamlined clinical research, more guidance speed new cures to patients. Jill Wechsler reports.

From the Editor

Blockchain 101 for Pharma Executives

With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you?

Insights for the Win

Lisa Henderson reports on the takeaways from last month's annual gathering of the Pharm Exec Editorial Advisory Board.

lorem ipsum